Light-activated cation channel and uses thereof

Patent metadata

Field	Value
Publication number	US-9278159-B2
Application number	US-45963806-A
Country	US
Kind code	B2
Filing date	Jul 24, 2006
Priority date	Jul 22, 2005
Publication date	Mar 8, 2016
Grant date	Mar 8, 2016

Abstract

The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.

First claim

What is claimed is:

1. A method of predicting potential ion channel modulating properties of a drug, the method comprising:
a) labeling a neuronal cell with a voltage sensitive dye, wherein the neuronal cell stably expresses a light-activated cation channel protein and an ion channel of interest, wherein the light-activated cation channel protein comprises an amino acid sequence having at least 75% amino acid sequence identity to ChR2;
b) exposing the neuronal cell to light, wherein the light is delivered at a frequency of at least 20 Hz;
c) monitoring the voltage sensitive dye to determine a first response in said cell;
d) exposing said dye-labeled neuronal cell to a candidate drug;
e) after exposing said cell to the candidate drug, further exposing said cell to light;
f) monitoring the voltage sensitive dye to determine a second response in said cell; and
g) comparing said first and second responses to identify a potential ion channel modulating property of said candidate drug, wherein a second response that is higher than the first response indicates that the candidate drug modulates the ion channel.

2. The method of claim 1 wherein the monitoring of the voltage sensitive dye comprises optical imaging of changes in fluorescence in said cell.

3. The method of claim 1 wherein the monitoring of the responses includes monitoring a signal transduction pathway in said cell.

4. The method of claim 3 wherein said monitoring of signal transduction is performed with an antibody, fluorescent small molecule, or a genetically encoded indicator.

5. The method of claim 1 wherein said method is performed to evaluate for selective effects of said candidate drug on said ion channel of interest.

6. The method of claim 1 wherein a differential effect of said candidate drug on channel splice variants, channel isoforms, channels expressed differentially in separate neuron types, channels expressed differentially in separate parts of the brain, channels expressed differentially in different organs, or channels that are expressed differentially over time is evaluated.

7. The method of claim 1 wherein said ion channel of interest is a HERG channel.

8. The method of claim 1 wherein the light-activated cation channel protein comprises an amino acid sequence having at least 85% amino acid sequence identity to ChR2.

9. The method of claim 1 wherein the light-activated cation channel protein comprises an amino acid sequence having at least 90% amino acid sequence identity to ChR2.

10. The method of claim 1 wherein the light-activated cation channel protein comprises an amino acid sequence having at least 95% amino acid sequence identity to ChR2.

11. The method of claim 1 wherein the light-activated cation channel protein is ChR2-310.

12. The method of claim 1 wherein the light-activated cation channel protein is Chop2-310.

13. The method of claim 1 , further including evaluating a differential effect of said candidate drug on: channel splice variants, channel isoforms, channels expressed differentially in different organs, or channels that are expressed differentially over time.

14. The method of claim 1 , further including the steps of
placing the cell into multiple wells of a multi-well plate;
exposing the cells to light pulses having a frequency of at least 20 Hz;
monitoring first-membrane-voltage responses in said cells;
exposing the cells in each well of the multi-well plate to a different candidate drug;
after exposing the cells to different candidate drugs,
exposing each of the cells to light pulses having a frequency of at least 20 Hz;
monitoring second-membrane-voltage responses in said cells; and
comparing each of the first-membrane-voltage responses to respective ones of the second membrane-voltage responses to identify a potential ion channel modulating property of each said different candidate drug.

15. The method of claim 1 , wherein the step of exposing the neuronal cell to light is implemented using a first light source and the step of monitoring a first response in said cell is implemented using a second light source and a beam splitter.

16. The method of claim 1 , wherein the ion channel of interest is a mutant ion channel responsible for a disease or a disorder.

17. The method of claim 1 , wherein the stably expressed ion channel of interest is a voltage-gated ion channel.

Assignees

• Deisseroth Karl
• Boyden Edward S
• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Boyden Edward S

Classifications

• A61P5/02

  of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title